## **Core Concept**
Multiple myeloma is a type of blood cancer characterized by the proliferation of malignant plasma cells in the bone marrow. The treatment of multiple myeloma involves various classes of drugs, including proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies. The choice of drug depends on several factors, including the patient's age, comorbidities, and previous treatment history.

## **Why the Correct Answer is Right**
Lenalidomide, a second-generation **immunomodulatory drug (IMiD)**, is considered a drug of choice in multiple myeloma due to its efficacy in combination with other agents. It works by enhancing T-cell and natural killer cell-mediated immunity and has direct anti-tumor effects. Lenalidomide has been shown to improve **progression-free survival (PFS)** and **overall survival (OS)** in patients with multiple myeloma.

## **Why Each Wrong Option is Incorrect**
* **Option A:** Melphalan is an **alkylating agent** used in the treatment of multiple myeloma, particularly in combination with prednisone (MP regimen) or as part of high-dose chemotherapy followed by autologous stem cell transplantation. However, it is not considered the first-line treatment in the current era.
* **Option B:** Bortezomib is a **proteasome inhibitor** that is effective in the treatment of multiple myeloma. While it is a first-line treatment option, lenalidomide-based regimens have become increasingly popular due to their efficacy and safety profile.
* **Option D:** Cyclophosphamide is an **alkylating agent** used in various cancer treatments, including multiple myeloma. However, it is not the preferred first-line treatment for multiple myeloma.

## **Clinical Pearl / High-Yield Fact**
A key clinical pearl is that the treatment landscape for multiple myeloma has evolved with the introduction of **lenalidomide**, **bortezomib**, and **daratumumab**, offering improved survival and quality of life for patients. Lenalidomide maintenance therapy has become a standard approach in the management of multiple myeloma.

## **Correct Answer:** . Lenalidomide